McKESSON CORPORATION
$105.22B- Market cap
- $102.70B
- Debt
- +$6.50B
- Cash
- −$3.98B
Capital structure 94% equity / 6% debt · EV / Revenue 0.26x · EV proxy / EBITDA proxy 16.19x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $102.70B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: MCK stock price at discount vs LLY $880.86 current versus $1.88K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LLY's multiple
Implied fair value · at MCK's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Multiple discount
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 94% equity / 6% debt · EV / Revenue 0.26x · EV proxy / EBITDA proxy 16.19x
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
LLY carries the larger enterprise value at $1.09T against $105.22B; MCK trades on the lower EV / Revenue multiple (0.26x vs 16.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
McKESSON CORPORATION · implied price per share
Bear
$630.54
Base
$765.28
Bull
$951.09
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CARDINAL HEALTH INC
MCK vs CAH
AbbVie Inc.
MCK vs ABBV
HENRY SCHEIN INC
MCK vs HSIC
PATTERSON COMPANIES, INC.
MCK vs PDCO
Zoetis Inc.
MCK vs ZTS
CVS HEALTH Corp
MCK vs CVS
Pfizer Inc.
MCK vs PFE
Merck & Co., Inc.
MCK vs MRK
Johnson & Johnson
MCK vs JNJ
Amgen Inc.
MCK vs AMGN
Bristol-Myers Squibb Company
MCK vs BMY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MCK can sustain mid-teens growth while preserving its current margin profile, then buying MCK is reasonable because it trades at a steep discount to LLY across key multiples and sits below the P/E-implied price.
MCK trades at a dramatic valuation discount to LLY across P/E, P/S, EV/EBITDA, and EV/Revenue, which suggests the market is paying far more for LLY’s growth and margin structure. The current price of $827.14 sits near the lower half of MCK’s historical band and well below the $1,875.29 implied by the P/E framework.
Supporting Metrics